Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.49 |
| ▸ | CDK9 | P50750 | 6/20 | 0.49 |
| ▸ | DYRK2 | Q92630 | 4/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL25347465 | 0.98 | DYRK1A (0.48) | DYRK1ACDK9DYRK2DYRK1BCLK1 | |
| SCHEMBL8574385 | 0.86 | DHODH (0.49) | DYRK1ACDK9DYRK2DYRK1BCLK1 | |
| SCHEMBL30533438 | 0.81 | DYRK1A (0.47) | DYRK1ACDK9DYRK2DYRK1BCLK1 | |
| SCHEMBL27903743 | 0.81 | DYRK1A (0.44) | DYRK1ACDK9DYRK2DYRK1BCLK1 | |
| SCHEMBL10416744 | 0.81 | DHODH (0.50) | DYRK1ACDK9DYRK2DYRK1BCLK1 | |
| SCHEMBL5388884 | 0.78 | ALDH1A1 (0.57) | DYRK1ACDK9DYRK2DYRK1BCLK1 | |
| SCHEMBL28219983 | 0.75 | TSHR (0.40) | ALDH1A1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL4787075 | 0.75 | PARP1 (0.46) | ALDH1A1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL28226188 | 0.73 | ALDH1A1 (0.59) | DYRK1ACDK9DYRK2DYRK1BCLK1 | |
| SCHEMBL8569654 | 0.72 | POLB (0.45) | ALDH1A1TSHRKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285786-A1 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-11-19 | — | — | US | claimed |
| JP-2009530408-A | — | — | 2009-08-27 | — | — | JP | claimed |
| CN-101495623-A | Method of modulating hematopoietic stem cell growth | CHILDRENS MEDICAL CT (US) | 2009-07-29 | — | — | CN | claimed |
| EP-1999255-A2 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | The Children's Medical Center Corporation (US) | 2008-12-10 | — | — | EP | claimed |
| WO-2007112084-A9 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | CHILDRENS MEDICAL CENTER (US) | 2007-11-22 | — | — | WO | claimed |
| WO-2007112084-A2 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2007-10-04 | — | — | WO | claimed |
| US-5576436-A | FLUORESCENT LABELED LIGANDS FOR MEASUREMENT OF RECEPTORS | PHARMACEUTICAL DISCOVERY CORPORATION (US) | 1996-11-19 | — | — | US | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-113966337-B | Compounds that modulate NMDA receptor activity, pharmaceutical compositions and uses thereof | 北京广为医药科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| WO-2023154014-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN FIKRET (TR) | 2023-08-17 | — | — | WO | disclosed |
| EP-4219507-A2 | THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-11648253-B2 | Thienopyrimidinone NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-05-16 | — | — | US | disclosed |
| EP-3386990-B1 | THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| WO-1997045446-A1 | GLYCINE TRANSPORTER-TRANSFECTED CELLS AND USES THEREOF | ALLELIX NEUROSCIENCE INC. (US) | 1997-12-04 | — | — | WO | disclosed |
| US-5576436-A | FLUORESCENT LABELED LIGANDS FOR MEASUREMENT OF RECEPTORS | PHARMACEUTICAL DISCOVERY CORPORATION (US) | 1996-11-19 | — | — | US | disclosed |
| CN-1133844-A | Osa-or thia-aliphatically bridged quinoxaline-2,3-diones | CIBA GEIGY AG (CH) | 1996-10-23 | — | — | CN | disclosed |
| CN-1120336-A | Imidazoloquinoxalinone derivatives as eaa antagonists | BASF AG (DE) | 1996-04-10 | — | — | CN | disclosed |
| CN-1098414-A | New triazolopyrimidones, their preparation method and application | BASF AG (DE) | 1995-02-08 | — | — | CN | disclosed |
| CN-1095380-A | Its preparation of novel triazoloquinazolines, and purposes | BASF AG (DE) | 1994-11-23 | — | — | CN | disclosed |
| WO-1993003382-A2 | CHARACTERIZATION OF SPECIFIC DRUG RECEPTORS WITH FLUORESCENT LIGANDS | PHARMACEUTICAL DISCOVERY CORPORATION (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648253-B2 | Thienopyrimidinone NMDA receptor modulators and uses thereof | GRIN1, GRIN2C, GRIN3A | DYRK1A 2460/4885CDK9 960/4885DYRK2 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.